|1.||Voelkel, Norbert F: 14 articles (02/2015 - 04/2002)|
|2.||Scigalla, Paul: 7 articles (07/2006 - 03/2002)|
|3.||Tuder, Rubin M: 6 articles (09/2015 - 04/2002)|
|4.||Kraskauskas, Donatas: 6 articles (02/2015 - 09/2010)|
|5.||Farkas, Laszlo: 6 articles (02/2015 - 10/2012)|
|6.||Lipson, Kenneth E: 6 articles (04/2008 - 03/2003)|
|7.||Mizuno, Shiro: 5 articles (02/2015 - 09/2010)|
|8.||Gomez-Arroyo, Jose: 5 articles (02/2015 - 11/2012)|
|9.||Bogaard, Harm J: 4 articles (02/2015 - 09/2010)|
|10.||Oka, Masahiko: 4 articles (11/2014 - 06/2011)|
04/01/1999 - "In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in a significant reduction of both the total and functional vascular density of the tumor microvasculature, which indicates an impaired vascularization as well as significant perfusion failure in treated tumors. "
01/01/2000 - "SU5416 treatment resulted in a significant reduction in tumor vascular density (p<0.05). "
05/01/2003 - "An inhibitor targeting VEGFRs in endothelial cells (SU5416) is effective against early-stage angiogenic lesions, but not large, well-vascularized tumors. "
04/01/2007 - "This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. "
05/01/2004 - "The patient was enrolled on a clinical study examining the efficacy of SU5416 in patients with metastatic cancer. "
01/01/2014 - "Here, we tested the hypothesis that combination therapy with two PAH drugs that target distinct biochemical pathways will provide superior efficacy relative to monotherapy in the rat SU5416 plus hypoxia (SU-Hx) model of severe angioproliferative PAH, which closely mimics the human condition. "
03/01/2013 - "The aim of this study was to determine whether inhibition of ET-1 signaling could reduce pulmonary oxidative stress and attenuate the progression of disease in rats with occlusive-angioproliferative PH induced by a single dose of SU5416 (200 mg/kg) and subsequent exposure to hypoxia for 21 days. "
11/01/2015 - "PAH was induced in mice using SU5416 and chronic hypoxia. "
02/01/2015 - "Angio-obliterative PAH and RV failure were induced in rats with a single injection of SU5416 followed by 4 weeks of exposure to hypoxia. "
12/01/2014 - "In conclusion, SU5416 combined with 3 weeks of hypoxia causes a more profound PH phenotype in mice than hypoxia alone. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
11/12/2004 - "These results indicate that SU5416 may be an effective agent for ovarian cancer treatment through the inhibition of VEGF and HIF-1 expression, and the activation of PI3K/AKT/p70S6K1 signaling pathway."
04/01/2003 - "In the present study, we investigated whether SU5416 could augment cisplatin-induced cytotoxicity in human ovarian cancer cells. "
11/12/2004 - "These results demonstrate that SU5416 inhibited VEGF and HIF-1alpha expression through the inhibition of PI3K/AKT/p70S6K1 pathway in ovarian cancer cells. "
08/01/2004 - "We have previously reported that SU5416 sensitizes ovarian cancer cells to cisplatin via suppression of nucleotide excision repair activity. "
04/01/2003 - "SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair."
08/01/2011 - "SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells."
01/01/2002 - "Our experimental data suggest that the angiogenesis inhibitor SU5416 may be beneficial in the treatment of solid tumors of childhood such as neuroblastoma."
01/01/2002 - "Treatment with SU5416 reduced the growth of neuroblastoma tumors by 65% without apparent toxicity. "
08/01/2011 - "We tested the efficacy of combination of SU5416 (SU), an inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR-2), and (-)-epigallocatechin-3-gallate (EGCG), a polyphenolic compound from green tea, for controlling growth of human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. "
09/20/2003 - "We report that antiangiogenic agents (arginine deiminase, SU5416 and DC101) inhibit in vivo growth of neuroblastomas with unfavorable properties and that these effects are potentiated by simultaneous irradiation. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/15/2003 - "A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia."
11/01/2001 - "Translational research in this study is intended to aid our understanding of the precise mechanisms by which SU5416 affects acute myeloid leukemia cells and the bone marrow microenvironment."
07/01/2001 - "Herein is described the successful treatment of a 65-year-old woman with SU5416, in second relapse of acute myeloid leukemia (AML) and refractory toward standard chemotherapy regimens. "
12/01/2006 - "Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416."
07/01/2004 - "Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia."
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||SU 6668 (SU6668)
|6.||Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
|9.||glucuronyl glucosamine glycan sulfate (Vessel)
|10.||tyrosine receptor (receptor, tyrosine)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Pneumonectomy (Lung Volume Reduction)